Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.